<?xml version="1.0" encoding="ISO-8859-1"?>

<rdf:RDF
 xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"
 xmlns="http://purl.org/rss/1.0/"
 xmlns:taxo="http://purl.org/rss/1.0/modules/taxonomy/"
 xmlns:dc="http://purl.org/dc/elements/1.1/"
 xmlns:syn="http://purl.org/rss/1.0/modules/syndication/"
 xmlns:prism="http://purl.org/rss/1.0/modules/prism/"
 xmlns:admin="http://webns.net/mvcb/"
>

<channel rdf:about="http://jdr.sagepub.com">
<title>Journal of Dental Research current issue</title>
<link>http://jdr.sagepub.com</link>
<description>Journal of Dental Research RSS feed -- current issue</description>
<prism:coverDisplayDate>Dec  1 2009 12:00:00:000AM</prism:coverDisplayDate>
<prism:publicationName>Journal of Dental Research</prism:publicationName>
<prism:issn>0022-0345</prism:issn>
<items>
 <rdf:Seq>
  <rdf:li rdf:resource="http://jdr.sagepub.com/cgi/content/abstract/88/12/1065?rss=1" />
  <rdf:li rdf:resource="http://jdr.sagepub.com/cgi/content/abstract/88/12/1077?rss=1" />
  <rdf:li rdf:resource="http://jdr.sagepub.com/cgi/reprint/88/12/1092?rss=1" />
  <rdf:li rdf:resource="http://jdr.sagepub.com/cgi/content/abstract/88/12/1096?rss=1" />
  <rdf:li rdf:resource="http://jdr.sagepub.com/cgi/content/abstract/88/12/1101?rss=1" />
  <rdf:li rdf:resource="http://jdr.sagepub.com/cgi/content/abstract/88/12/1107?rss=1" />
  <rdf:li rdf:resource="http://jdr.sagepub.com/cgi/content/abstract/88/12/1113?rss=1" />
  <rdf:li rdf:resource="http://jdr.sagepub.com/cgi/content/abstract/88/12/1119?rss=1" />
  <rdf:li rdf:resource="http://jdr.sagepub.com/cgi/content/abstract/88/12/1125?rss=1" />
  <rdf:li rdf:resource="http://jdr.sagepub.com/cgi/content/abstract/88/12/1131?rss=1" />
  <rdf:li rdf:resource="http://jdr.sagepub.com/cgi/content/abstract/88/12/1137?rss=1" />
  <rdf:li rdf:resource="http://jdr.sagepub.com/cgi/content/abstract/88/12/1142?rss=1" />
  <rdf:li rdf:resource="http://jdr.sagepub.com/cgi/content/abstract/88/12/1148?rss=1" />
 </rdf:Seq>
</items>
<image rdf:resource="http://jdr.sagepub.com:80/icons/banner/title.gif" />
</channel>

<image rdf:about="http://jdr.sagepub.com:80/icons/banner/title.gif">
<title>Journal of Dental Research</title>
<url>http://jdr.sagepub.com:80/icons/banner/title.gif</url>
<link>http://jdr.sagepub.com</link>
</image>

<item rdf:about="http://jdr.sagepub.com/cgi/content/abstract/88/12/1065?rss=1">
<title><![CDATA[Pre-clinical Models for Oral and Periodontal Reconstructive Therapies]]></title>
<link>http://jdr.sagepub.com/cgi/content/abstract/88/12/1065?rss=1</link>
<description><![CDATA[
<p>The development of new medical formulations (NMF) for reconstructive therapies has considerably improved the available treatment options for individuals requiring periodontal repair or oral implant rehabilitation. Progress in tissue engineering and regenerative medicine modalities strongly depends on validated pre-clinical research. Pre-clinical testing has contributed to the recent approval of NMF such as GEM 21S<sup>&reg;</sup> and INFUSE<sup>&reg;</sup> bone grafts for periodontal and oral regenerative therapies. However, the selection of a suitable pre-clinical model for evaluation of the safety and efficacy of a NMF remains a challenge. This review is designed to serve as a primer to choose the appropriate pre-clinical models for the evaluation of NMF in situations requiring periodontal or oral reconstruction. Here, we summarize commonly used pre-clinical models and provide examples of screening and functional studies of NMF that can be translated into clinical use.</p>
]]></description>
<dc:creator><![CDATA[Pellegrini, G., Seol, Y.J., Gruber, R., Giannobile, W.V.]]></dc:creator>
<dc:date>Fri, 20 Nov 2009 15:47:48 PST</dc:date>
<dc:identifier>info:doi/10.1177/0022034509349748</dc:identifier>
<dc:title><![CDATA[Pre-clinical Models for Oral and Periodontal Reconstructive Therapies]]></dc:title>
<dc:publisher>International and American Associations for Dental Research</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>88</prism:volume>
<prism:endingPage>1076</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>1065</prism:startingPage>
<prism:section>CRITICAL REVIEWS IN ORAL BIOLOGY &amp; MEDICINE</prism:section>
</item>

<item rdf:about="http://jdr.sagepub.com/cgi/content/abstract/88/12/1077?rss=1">
<title><![CDATA[Engineering Craniofacial Structures: Facing the Challenge]]></title>
<link>http://jdr.sagepub.com/cgi/content/abstract/88/12/1077?rss=1</link>
<description><![CDATA[
<p>The human innate regenerative ability is known to be limited by the intensity of the insult together with the availability of progenitor cells, which may cause certain irreparable damage. It is only recently that the paradigm of tissue engineering found its way to the treatment of irreversibly affected body structures with the challenge of reconstructing the lost part. In the current review, we underline recent trials that target engineering of human craniofacial structures, mainly bone, cartilage, and teeth. We analyze the applied engineering strategies relative to the selection of cell types to lay down a specific targeted tissue, together with their association with an escorting scaffold for a particular engineered site, and discuss their necessity to be sustained by growth factors. Challenges and expectations for facial skeletal engineering are discussed in the context of future treatment.</p>
]]></description>
<dc:creator><![CDATA[Zaky, S.H., Cancedda, R.]]></dc:creator>
<dc:date>Fri, 20 Nov 2009 15:47:49 PST</dc:date>
<dc:identifier>info:doi/10.1177/0022034509349926</dc:identifier>
<dc:title><![CDATA[Engineering Craniofacial Structures: Facing the Challenge]]></dc:title>
<dc:publisher>International and American Associations for Dental Research</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>88</prism:volume>
<prism:endingPage>1091</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>1077</prism:startingPage>
<prism:section>CRITICAL REVIEWS IN ORAL BIOLOGY &amp; MEDICINE</prism:section>
</item>

<item rdf:about="http://jdr.sagepub.com/cgi/reprint/88/12/1092?rss=1">
<title><![CDATA[Walter Loesche--a Maverick in Translational Research in Dentistry]]></title>
<link>http://jdr.sagepub.com/cgi/reprint/88/12/1092?rss=1</link>
<description><![CDATA[]]></description>
<dc:creator><![CDATA[Banas, J.A.]]></dc:creator>
<dc:date>Fri, 20 Nov 2009 15:47:49 PST</dc:date>
<dc:identifier>info:doi/10.1177/0022034509351511</dc:identifier>
<dc:title><![CDATA[Walter Loesche--a Maverick in Translational Research in Dentistry]]></dc:title>
<dc:publisher>International and American Associations for Dental Research</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>88</prism:volume>
<prism:endingPage>1095</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>1092</prism:startingPage>
<prism:section>DISCOVERY!</prism:section>
</item>

<item rdf:about="http://jdr.sagepub.com/cgi/content/abstract/88/12/1096?rss=1">
<title><![CDATA[Effects of Chemical Cross-linkers on Caries-affected Dentin Bonding]]></title>
<link>http://jdr.sagepub.com/cgi/content/abstract/88/12/1096?rss=1</link>
<description><![CDATA[
<p>The achievement of a strong and stable bond between composite resin and dentin remains a challenge in restorative dentistry. Over the past two decades, dental materials have been substantially improved, with better handling and bonding characteristics. However, little attention has been paid to the contribution of collagen structure/stability to bond strength. We hypothesized that the induction of cross-linking in dentin collagen improves dentin collagen stability and bond strength. This study investigated the effects of glutaraldehyde-and grape seed extract-induced cross-linking on the dentin bond strengths of sound and caries-affected dentin, and on the stability of dentin collagen. Our results demonstrated that the application of chemical cross-linking agents to etched dentin prior to bonding procedures significantly enhanced the dentin bond strengths of caries-affected and sound dentin. Glutaraldehyde and grape seed extract significantly increased dentin collagen stability in sound and caries-affected dentin, likely <I>via</I> distinct mechanisms.</p>
]]></description>
<dc:creator><![CDATA[Macedo, G.V., Yamauchi, M., Bedran-Russo, A.K.]]></dc:creator>
<dc:date>Fri, 20 Nov 2009 15:47:49 PST</dc:date>
<dc:identifier>info:doi/10.1177/0022034509351001</dc:identifier>
<dc:title><![CDATA[Effects of Chemical Cross-linkers on Caries-affected Dentin Bonding]]></dc:title>
<dc:publisher>International and American Associations for Dental Research</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>88</prism:volume>
<prism:endingPage>1100</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>1096</prism:startingPage>
<prism:section>BIOMATERIALS &amp; BIOENGINEERING</prism:section>
</item>

<item rdf:about="http://jdr.sagepub.com/cgi/content/abstract/88/12/1101?rss=1">
<title><![CDATA[Inhibition of Enzymatic Degradation of Adhesive-Dentin Interfaces]]></title>
<link>http://jdr.sagepub.com/cgi/content/abstract/88/12/1101?rss=1</link>
<description><![CDATA[
<p>Adhesive procedures activate dentin-associated matrix metalloproteinases (MMPs), and so iatrogenically initiate bond degradation. We hypothesized that adding MMP inhibitors to adhesive primers may prevent this endogenous enzymatic degradation, thereby improving bond durability. A non-specific MMP inhibitor (chlorhexidine) and a MMP-2/9-specific inhibitor (SB-3CT) were admixed to the primers of an etch &amp; rinse and a self-etch adhesive, both considered as gold-standard adhesives within their respective categories. For dentin powder exposed to the adhesives under clinical application conditions, gelatin zymography revealed the release of MMP-2 (not of MMP-9) by the etch &amp; rinse adhesive, while no release of enzymes could be detected for the mild self-etch adhesive, most likely because of its limited dentin demineralization effect. The built-in MMP inhibitors appeared effective in reducing bond degradation only for the etch &amp; rinse adhesive, and not for the self-etch adhesive. Water sorption of adhesive interfaces most likely remains the principal mechanism of bond degradation, while endogenous enzymes appear to contribute to bond degradation of only etch &amp; rinse adhesives.</p>
]]></description>
<dc:creator><![CDATA[De Munck, J., Van den Steen, P.E., Mine, A., Van Landuyt, K.L., Poitevin, A., Opdenakker, G., Van Meerbeek, B.]]></dc:creator>
<dc:date>Fri, 20 Nov 2009 15:47:49 PST</dc:date>
<dc:identifier>info:doi/10.1177/0022034509346952</dc:identifier>
<dc:title><![CDATA[Inhibition of Enzymatic Degradation of Adhesive-Dentin Interfaces]]></dc:title>
<dc:publisher>International and American Associations for Dental Research</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>88</prism:volume>
<prism:endingPage>1106</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>1101</prism:startingPage>
<prism:section>BIOMATERIALS &amp; BIOENGINEERING</prism:section>
</item>

<item rdf:about="http://jdr.sagepub.com/cgi/content/abstract/88/12/1107?rss=1">
<title><![CDATA[Appositional Bone Formation by OCP-Collagen Composite]]></title>
<link>http://jdr.sagepub.com/cgi/content/abstract/88/12/1107?rss=1</link>
<description><![CDATA[
<p>Synthetic octacalcium phosphate (OCP) has been shown to enhance bone formation and to biodegrade if implanted into bone defects. Here, we hypothesized that an OCP-atelocollagen complex (OCP/Col) is biodegradable and can induce bone formation in a thickness-dependent manner when implanted into the calvaria. OCP/Col disks (diameter, 9 mm; thickness, 1 or 3 mm) were implanted into a subperiosteal pocket in the calvaria of 12-week-old Wistar rats for 4, 8, and 12 weeks and subsequent bone formation was monitored. X-ray diffraction analysis and Fourier transform infrared spectroscopy showed that OCP in the OCP/Col implants was converted into a carbonate-rich apatite after 4 weeks. Although thinner disks tended to be replaced by new bone, thicker disks were progressively resorbed by osteoclast-like cells until 12 weeks, possibly <I>via</I> the increased mechanical load in the subperiosteal pocket. Therefore, OCP/Col can increase appositional intra-membranous bone formation if the appropriate size of the implant is applied.</p>
]]></description>
<dc:creator><![CDATA[Suzuki, Y., Kamakura, S., Honda, Y., Anada, T., Hatori, K., Sasaki, K., Suzuki, O.]]></dc:creator>
<dc:date>Fri, 20 Nov 2009 15:47:49 PST</dc:date>
<dc:identifier>info:doi/10.1177/0022034509351378</dc:identifier>
<dc:title><![CDATA[Appositional Bone Formation by OCP-Collagen Composite]]></dc:title>
<dc:publisher>International and American Associations for Dental Research</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>88</prism:volume>
<prism:endingPage>1112</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>1107</prism:startingPage>
<prism:section>BIOMATERIALS &amp; BIOENGINEERING</prism:section>
</item>

<item rdf:about="http://jdr.sagepub.com/cgi/content/abstract/88/12/1113?rss=1">
<title><![CDATA[Pharmacological Retention of Oral Mucosa Progenitor/Stem Cells]]></title>
<link>http://jdr.sagepub.com/cgi/content/abstract/88/12/1113?rss=1</link>
<description><![CDATA[
<p>Oral mucosa progenitor/stem cells reside as a small-sized cell population that eventually differentiates concurrently with an increase in cell size. Activation of the mammalian target of rapamycin (mTOR) leads to an increase in cell size. We hypothesized that rapamycin, a specific inhibitor of mTOR, will maintain primary human oral keratinocytes as a small-sized, undifferentiated cell population capable of retaining their proliferative capacity. Primary, rapamycin-treated (2 nM, 20 nM) oral keratinocytes showed a diminished cell size that correlated with a higher clonogenicity, a longer-term proliferative potential, and a slower cycling cell population concurrent with decreased expression of a differentiation marker when compared with untreated cells. Only the 2-nM rapamycin-treated oral keratinocytes maintained their ability to regenerate oral mucosa <I>in vitro</I> after 15 weeks of culture. Rapamycin, a Food and Drug Administration-approved drug, may have applicability for use in creating a highly proliferative cell population for use in regenerative medicine.</p>
]]></description>
<dc:creator><![CDATA[Izumi, K., Inoki, K., Fujimori, Y., Marcelo, C.L., Feinberg, S.E.]]></dc:creator>
<dc:date>Fri, 20 Nov 2009 15:47:49 PST</dc:date>
<dc:identifier>info:doi/10.1177/0022034509350559</dc:identifier>
<dc:title><![CDATA[Pharmacological Retention of Oral Mucosa Progenitor/Stem Cells]]></dc:title>
<dc:publisher>International and American Associations for Dental Research</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>88</prism:volume>
<prism:endingPage>1118</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>1113</prism:startingPage>
<prism:section>BIOLOGICAL</prism:section>
</item>

<item rdf:about="http://jdr.sagepub.com/cgi/content/abstract/88/12/1119?rss=1">
<title><![CDATA[PDK1 Regulates Chemotaxis in Human Neutrophils]]></title>
<link>http://jdr.sagepub.com/cgi/content/abstract/88/12/1119?rss=1</link>
<description><![CDATA[
<p>Phosphoinositide-dependent kinase (PDK1) plays a central role in signal transduction mediated by phosphatidylinositol 3-kinases (PI3K) and regulates cellular functions in neutrophils. Neutrophils from individuals diagnosed with localized aggressive periodontitis (LAP) present an <I>in vivo</I> phenotype with depressed chemotaxis. The aim of this study was to test the hypothesis that PDK1 regulates chemotaxis in neutrophils and is responsible for the abnormal neutrophil chemotaxis LAP. Neutrophil chemotaxis was significantly suppressed by the PDK1 inhibitor staurosporine. When cells were transfected with PDK1 siRNA, there was a significant reduction in chemotaxis, while superoxide generation was not significantly affected. In primary neutrophils from persons with LAP, PDK1 expression and activation levels were significantly reduced, and this reduction was associated with the reduced phosphorylation of Akt (Thr308) and chemotaxis. Analysis of these data demonstrates that PDK1 is essential for the chemotactic migration of neutrophils, and in the absence of PDK1, neutrophil chemotaxis is impaired.</p>
]]></description>
<dc:creator><![CDATA[Yagi, M., Kantarci, A., Iwata, T., Omori, K., Ayilavarapu, S., Ito, K., Hasturk, H., Van Dyke, T.E.]]></dc:creator>
<dc:date>Fri, 20 Nov 2009 15:47:49 PST</dc:date>
<dc:identifier>info:doi/10.1177/0022034509349402</dc:identifier>
<dc:title><![CDATA[PDK1 Regulates Chemotaxis in Human Neutrophils]]></dc:title>
<dc:publisher>International and American Associations for Dental Research</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>88</prism:volume>
<prism:endingPage>1124</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>1119</prism:startingPage>
<prism:section>BIOLOGICAL</prism:section>
</item>

<item rdf:about="http://jdr.sagepub.com/cgi/content/abstract/88/12/1125?rss=1">
<title><![CDATA[MAP Kinase Phosphatase-1 Protects against Inflammatory Bone Loss]]></title>
<link>http://jdr.sagepub.com/cgi/content/abstract/88/12/1125?rss=1</link>
<description><![CDATA[
<p>The mitogen-activated protein (MAP) kinase phosphatase (MKP) family plays an important function in regulating the pro-inflammatory cytokines by deactivating MAP kinases. MKP-1 is essential for the dephosphorylation of p38 MAP kinase that regulates expression of IL-6, TNF-, and IL-1&beta;. We hypothesized that MKP-1 regulates inflammatory bone loss in experimental periodontitis. Wild-type and <I>Mkp</I>-1<sup>&ndash;/&ndash;</sup> mice received <I>A. actinomycetemcomitans</I> LPS injection in the palatal region or PBS control 3 times/wk for 30 days. Mice were killed, and maxillae were assessed by microcomputed tomography, histological analysis, and TRAP staining for measurement of bone loss, extent of inflammation, and degree of osteoclastogenesis. Results indicated that, in LPS-injected <I>Mkp</I>-1<sup>&ndash;/&ndash;</sup> mice, significantly greater bone loss occurred with more inflammatory infiltrate and a significant increase in osteoclastogenesis compared with <I>Mkp</I>-1<sup>&ndash;/&ndash;</sup> control sites or either wild-type group. Analysis of these data indicates that MKP-1 plays a key role in the regulation of inflammatory bone loss.</p>
]]></description>
<dc:creator><![CDATA[Sartori, R., Li, F., Kirkwood, K.L.]]></dc:creator>
<dc:date>Fri, 20 Nov 2009 15:47:49 PST</dc:date>
<dc:identifier>info:doi/10.1177/0022034509349306</dc:identifier>
<dc:title><![CDATA[MAP Kinase Phosphatase-1 Protects against Inflammatory Bone Loss]]></dc:title>
<dc:publisher>International and American Associations for Dental Research</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>88</prism:volume>
<prism:endingPage>1130</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>1125</prism:startingPage>
<prism:section>BIOLOGICAL</prism:section>
</item>

<item rdf:about="http://jdr.sagepub.com/cgi/content/abstract/88/12/1131?rss=1">
<title><![CDATA[Cyclosporin A and Phenytoin Modulate Inflammatory Responses]]></title>
<link>http://jdr.sagepub.com/cgi/content/abstract/88/12/1131?rss=1</link>
<description><![CDATA[
<p>Gingival overgrowth is a common side-effect of administration of the immunosuppressant cyclosporin A and the anti-epileptic drug phenytoin. While cyclosporin-induced gingival overgrowth is often accompanied by gingival inflammation, phenytoin-induced gingival overgrowth usually forms fibrotic lesions. To determine whether these drugs alter the inflammatory responses of gingival fibroblasts, we investigated the effects of cyclosporin and phenytoin on Toll-like receptor (TLR)-mediated responses to microbial components. In Chinese hamster ovary reporter cell lines, cyclosporin alone triggered signaling, whereas phenytoin down-regulated signaling induced by the TLR2 or TLR4 ligand. In human gingival fibroblasts, cyclosporin alone did not induce evident inflammatory responses, but augmented the expression of CD54 and the production of interleukin (IL)-6 and IL-8 induced by TLR ligands, whereas phenytoin attenuated those responses. Cyclosporin also augmented CD54 expression in gingiva of mice injected with lipopolysaccharide. These results indicated that cyclosporin positively and phenytoin negatively modulated inflammatory responses of human gingival fibroblasts.</p>
]]></description>
<dc:creator><![CDATA[Suzuki, A.M.M., Yoshimura, A., Ozaki, Y., Kaneko, T., Hara, Y.]]></dc:creator>
<dc:date>Fri, 20 Nov 2009 15:47:49 PST</dc:date>
<dc:identifier>info:doi/10.1177/0022034509350566</dc:identifier>
<dc:title><![CDATA[Cyclosporin A and Phenytoin Modulate Inflammatory Responses]]></dc:title>
<dc:publisher>International and American Associations for Dental Research</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>88</prism:volume>
<prism:endingPage>1136</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>1131</prism:startingPage>
<prism:section>BIOLOGICAL</prism:section>
</item>

<item rdf:about="http://jdr.sagepub.com/cgi/content/abstract/88/12/1137?rss=1">
<title><![CDATA[Genetic Risk Factors for Periodontitis in a Japanese Population]]></title>
<link>http://jdr.sagepub.com/cgi/content/abstract/88/12/1137?rss=1</link>
<description><![CDATA[
<p>Genetic variants at multiple loci have been shown to be associated with susceptibility to periodontitis. To better assess the genetic risk factors for periodontitis, we performed a case-control study in 319 Japanese individuals with periodontitis (172 aggressive and 147 chronic disease) and 303 race-matched healthy control individuals. Thirty-five functional gene polymorphisms that had been previously associated with immune responses were genotyped. For all gene polymorphisms tested, no significant differences were observed in the allele frequencies of persons with aggressive, chronic, and combined (aggressive and chronic) periodontitis, compared with control individuals. Multiple logistic regression analysis revealed a significant association of the vitamin D receptor +1056 T/C polymorphism with susceptibility to chronic periodontitis, after adjustment for age, gender, and smoking status (P = 0.002). These results suggest that none of the polymorphisms tested was strongly associated with periodontitis in a Japanese population. However, the vitamin D receptor +1056 polymorphism may be related to chronic periodontitis.</p>
]]></description>
<dc:creator><![CDATA[Kobayashi, T., Nagata, T., Murakami, S., Takashiba, S., Kurihara, H., Izumi, Y., Numabe, Y., Watanabe, H., Kataoka, M., Nagai, A., Hayashi, J., Ohyama, H., Okamatsu, Y., Inagaki, Y., Tai, H., Yoshie, H.]]></dc:creator>
<dc:date>Fri, 20 Nov 2009 15:47:49 PST</dc:date>
<dc:identifier>info:doi/10.1177/0022034509350037</dc:identifier>
<dc:title><![CDATA[Genetic Risk Factors for Periodontitis in a Japanese Population]]></dc:title>
<dc:publisher>International and American Associations for Dental Research</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>88</prism:volume>
<prism:endingPage>1141</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>1137</prism:startingPage>
<prism:section>CLINICAL</prism:section>
</item>

<item rdf:about="http://jdr.sagepub.com/cgi/content/abstract/88/12/1142?rss=1">
<title><![CDATA[Immunomodulatory Activity of IL-27 in Human Periapical Lesions]]></title>
<link>http://jdr.sagepub.com/cgi/content/abstract/88/12/1142?rss=1</link>
<description><![CDATA[
<p>IL-27, a cytokine with pro-inflammatory and anti-inflammatory properties, is a new member of the IL-6/IL-12 family, whose function in periapical lesions is unknown. We hypothesized that the production of IL-27 and its effect depend upon the type of immune/inflammatory response and clinical presentation of periapical lesions. We tested this hypothesis by studying the expression and function of IL-27 in human periapical lesions, both <I>in situ</I> and in culture. Immunohistochemistry demonstrated the strongest expression of IL-27 by endothelial cells and mononuclear phagocytes. Its production by periapical lesion mononuclear cells (PL-MNC), especially in symptomatic lesions, was significantly higher compared with that in peripheral blood MNC and correlated with the frequency of CD14<sup>+</sup> and CD3<sup>+</sup> cells. Exogenous IL-27 stimulated Th1 and down-regulated Th17 cytokine production by PL-MNC from symptomatic lesions, but down-regulated Th1 and Th2 responses in asymptomatic lesions. These findings suggest that IL-27 is an immunomodulatory cytokine in periapical lesions, with complex biological effects.</p>
]]></description>
<dc:creator><![CDATA[Colic, M., Gazivoda, D., Majstorovic, I., Dragicevic, A., Vasilijic, S., Rudolf, R., Milosavljevic, P., Vucevic, D.]]></dc:creator>
<dc:date>Fri, 20 Nov 2009 15:47:49 PST</dc:date>
<dc:identifier>info:doi/10.1177/0022034509351407</dc:identifier>
<dc:title><![CDATA[Immunomodulatory Activity of IL-27 in Human Periapical Lesions]]></dc:title>
<dc:publisher>International and American Associations for Dental Research</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>88</prism:volume>
<prism:endingPage>1147</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>1142</prism:startingPage>
<prism:section>CLINICAL</prism:section>
</item>

<item rdf:about="http://jdr.sagepub.com/cgi/content/abstract/88/12/1148?rss=1">
<title><![CDATA[Regression of Post-orthodontic Lesions by a Remineralizing Cream]]></title>
<link>http://jdr.sagepub.com/cgi/content/abstract/88/12/1148?rss=1</link>
<description><![CDATA[
<p>Orthodontic patients have an increased risk of white-spot lesion formation. A clinical trial was conducted to test whether, in a post-orthodontic population using fluoride toothpastes and receiving supervised fluoride mouthrinses, more lesions would regress in participants using a remineralizing cream containing casein phosphopeptide- amorphous calcium phosphate compared with a placebo. Forty-five participants (aged 12&ndash;18 yrs) with 408 white-spot lesions were recruited, with 23 participants randomized to the remineralizing cream and 22 to the placebo. Product was applied twice daily after fluoride toothpaste use for 12 weeks. Clinical assessments were performed according to ICDAS II criteria. Transitions between examinations were coded as progressing, regressing, or stable. Ninety-two percent of lesions were assessed as code 2 or 3. For these lesions, 31% more had regressed with the remineralizing cream than with the placebo (OR = 2.3, P = 0.04) at 12 weeks. Significantly more post-orthodontic white-spot lesions regressed with the remineralizing cream compared with a placebo over 12 weeks.</p>
]]></description>
<dc:creator><![CDATA[Bailey, D.L., Adams, G.G., Tsao, C.E., Hyslop, A., Escobar, K., Manton, D. J., Reynolds, E.C., Morgan, M.V.]]></dc:creator>
<dc:date>Fri, 20 Nov 2009 15:47:49 PST</dc:date>
<dc:identifier>info:doi/10.1177/0022034509347168</dc:identifier>
<dc:title><![CDATA[Regression of Post-orthodontic Lesions by a Remineralizing Cream]]></dc:title>
<dc:publisher>International and American Associations for Dental Research</dc:publisher>
<prism:number>12</prism:number>
<prism:volume>88</prism:volume>
<prism:endingPage>1153</prism:endingPage>
<prism:publicationDate>2009-12-01</prism:publicationDate>
<prism:startingPage>1148</prism:startingPage>
<prism:section>CLINICAL</prism:section>
</item>

</rdf:RDF>